Evidence map›Paper›PMID 39238780›Full record

ArticlePreventive medicine reports2024

Association of chronic opioid therapy and opioid use disorder with COVID-19-related hospitalization and mortality: Evidence from three health systems in the United States.

Anh P Nguyen, Ingrid A Binswanger, Komal J Narwaney, Morgan A Ford, David L McClure, Deborah J Rinehart, Jason A Lyons, Jason M Glanz

Abstract read
In one paragraph

Article in Preventive medicine reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anh P NguyenInstitute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.
Ingrid A BinswangerInstitute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.
Komal J NarwaneyInstitute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.
Morgan A FordInstitute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.
David L McClureCenter for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA.
Deborah J RinehartDivision of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Jason A LyonsInstitute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.
Jason M GlanzInstitute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.

Funding

Assessing the Safety and Effectiveness of Opioid Tapering in Large Health SystemsR01DA047537 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI BINSWANGER, INGRID A, GLANZ, JASON M · 2019 to 2022
$2.6M
NIDA NIH HHS R01 DA047537
6 · The paper itself

Abstract

Objective: Chronic opioid use can lead to detrimental effects on the immune and various organ systems that put individuals prescribed chronic opioid therapy (COT) for pain and those with an opioid use disorder (OUD) at risk for severe COVID-19 disease. We assessed the association of COT and OUD with COVID-19-related hospitalization and death to inform targeted interventions to improve clinical outcomes in COVID-19 patients who use opioids. Methods: We conducted a retrospective cohort study of adults ages ≥ 18 with laboratory-confirmed SARS-CoV-2 infection in 2020 and 2021 from three US health systems. We used Cox proportional hazards regression to estimate the 30-day risk of COVID-19-related hospitalization and death associated with two opioid exposures (COT and OUD) following an infection. Results: The study cohort included 53,123 patients with SARS-CoV-2 infection and a mean (SD) age of 45.1 (16.5), of whom 1,059 (2.0 %) were exposed to COT and 269 (0.5 %) had an OUD diagnosis in the year prior to infection. There were 2,270 observed COVID-19-related hospitalizations or deaths (1.6 per 1,000 person-days, 95 % CI 1.5-1.7). In the fully adjusted model, COT was not associated with increased risk (HR 1.19; 95 % CI, 0.98-1.43), while past-year OUD was independently associated with severe COVID-19 disease (HR 1.82; 95 % CI, 1.18-2.80). Past-year OUD remained associated with increased risk in post-hoc analysis with COVID-19-related hospitalization alone as the outcome (HR 2.00; 95 % CI, 1.30-3.08). Conclusions: Past-year OUD is a potential independent risk factor for severe COVID-19 disease that warrants monitoring to improve the prognosis of patients with COVID-19.

Indexed as

Chronic opioid therapyCOVID-19Health servicesOpioid use disorderRisk prevention

Identifiers

PMID39238780
PMCPMC11374958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.